Lupus (SLE): vizsgálatok itt: Kína
163 trials · From ClinicalTrials.gov, checked 2026. november 13.. Ask the study team whether a trial fits you.
- No phaseTaking peopleAnti-CD19 IL-10/IL15 CAR-NK Cells in Refractory/Relapsed Autoimmune Diseases
- Where
- Hangzhou
- Életkor
- 18 év to 65 év
- People
- 15
- Run by
- Second Affiliated Hospital, Zhejiang University, School of Medicine
See details and how to joinNCT06614270 - 1. fázisTaking peopleClinical Trial of CD19 Targeted CAR-T Cell in Refractory Adult SLE
- Where
- Hangzhou, Hefei
- Életkor
- 18 év and over
- People
- 12
- Run by
- Chongqing Precision Biotech Co., Ltd
See details and how to joinNCT06892145 - No phaseNot yet taking people in KínaA Study of CD19 UCAR-T Cells in Subjects With Autoimmune Diseases
- Where
- Tianjin
- Életkor
- 18 év to 65 év
- People
- 24
- Run by
- Institute of Hematology & Blood Diseases Hospital, China
See details and how to joinNCT07212322 - 1/2. fázisTaking peopleA Study of APG-2575 in Patients With Mild-to-moderate Systemic Lupus Erythematosus.
- Where
- Shanghai
- Életkor
- 18 év to 65 év
- People
- 40
- Run by
- Ascentage Pharma Group Inc.
See details and how to joinNCT06182969 - Korai 1. fázisTaking peopleAllogeneic UCB-derived CAR-T for SLE
- Where
- Chengdu, Yancheng
- Életkor
- 18 év to 75 év
- People
- 48
- Run by
- Chengdu Ucello Biotechnology Co., Ltd.
See details and how to joinNCT07274059 - Korai 1. fázisNot yet taking people in KínaCD19/BCMA CAR-T for SLE
- Where
- Chengdu
- Életkor
- 18 év to 75 év
- People
- 24
- Run by
- Chengdu Ucello Biotechnology Co., Ltd.
See details and how to joinNCT07266337 - 2. fázisTaking peopleA Phase II Clinical Study on the Efficacy and Safety of SHR-2173 Injection in the Treatment of Patients With Active Lupus Nephritis
- Where
- Nanjing
- Életkor
- 18 év to 70 év
- People
- 51
- Run by
- Guangdong Hengrui Pharmaceutical Co., Ltd
See details and how to joinNCT07229742 - 1. fázisTaking peopleBlinatumomab in Refractory Active Childhood Systemic Lupus Erythematosus
- Where
- Hangzhou
- Életkor
- 5 év and over
- People
- 6
- Run by
- Mao Jianhua
See details and how to joinNCT06789107 - 1/2. fázisTaking peopleThe Purpose of This Study is to Evaluate the Efficacy and Safety of 626 in the Treatment of SLE
- Where
- Beijing
- Életkor
- 18 év to 70 év
- People
- 198
- Run by
- Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.
See details and how to joinNCT07185269 - 1. fázisTaking peopleSafety, Efficacy and Cellular Metabolic Dynamics of ct1192 in Patients With Moderate to Severe Refractory SLE
- Where
- Wuhan
- Életkor
- 18 év to 60 év
- People
- 12
- Run by
- Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
See details and how to joinNCT07031713 - 2. fázisTaking peopleA Study to Evaluate the Efficacy, Safety, and Tolerability of Human Sialidase Fusion Protein (HLX79) in Combination With Rituximab Injection Versus Placebo in Patients With Active Glomerulonephritis
- Where
- Beijing, Changsha, Guangzhou, Hangzhou, Hefei, Luoyang, Nanchang, Nanjing, Shanghai, Wuhan, Xiamen, Xi’an, Yangzhou
- Életkor
- 18 év to 75 év
- People
- 24
- Run by
- Shanghai Henlius Biotech
See details and how to joinNCT07038382 - 1. fázisTaking peopleStudy of Ultra-Fast CD19 CAR-T Therapy for Refractory SLE
- Where
- Hangzhou
- Életkor
- 5 év and over
- People
- 18
- Run by
- The Children's Hospital of Zhejiang University School of Medicine
See details and how to joinNCT07233642 - 1. fázisTaking peopleCAR T-cell Therapy Targeting CD19 and BCMA in Patients With Relapse/Refractory Autoimmune Diseases
- Where
- Tianjin
- Életkor
- 18 év and over
- People
- 12
- Run by
- Institute of Hematology & Blood Diseases Hospital, China
See details and how to joinNCT06941129 - 1. fázisTaking peopleClinical Study of A-319 in the Treatment of Active/Refractory Systemic Lupus Erythematosus
- Where
- Taiyuan, Wuhan
- Életkor
- 18 év to 60 év
- People
- 25
- Run by
- Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
See details and how to joinNCT06400537 - Korai 1. fázisTaking peopleSafety Study of CC312 in Autoimmune Disease Patients
- Where
- Tianjin
- Életkor
- 18 év and over
- People
- 18
- Run by
- CytoCares Inc
See details and how to joinNCT06888960 - 1. fázisTaking peopleSafety and Efficacy Study of CC312 for Moderate to Severe SLE
- Where
- Chengdu
- Életkor
- 18 év to 65 év
- People
- 32
- Run by
- CytoCares Inc
See details and how to joinNCT07177911 - No phaseTaking peopleAnti CD19/BCMA CAR Gene Therapy for Autoimmune Diseases
- Where
- Hefei
- Életkor
- 18 év and over
- People
- 18
- Run by
- Anhui Provincial Hospital
See details and how to joinNCT07121777 - 1. fázisTaking peopleInaticabtagene Autoleucel Injection in the Treatment of Refractory Systemic Lupus Erythematosus-related Immune Thrombocytopenia
- Where
- Beijing
- Életkor
- 18 év to 70 év
- People
- 12
- Run by
- Juventas Cell Therapy Ltd.
See details and how to joinNCT06826430 - 1. fázisTaking peopleA Study of C-CAR168 in the Treatment of Autoimmune Diseases Refractory to Standard Therapy
- Where
- Shanghai
- Életkor
- 18 év to 70 év
- People
- 30
- Run by
- RenJi Hospital
See details and how to joinNCT06249438 - No phaseNot yet taking people in KínaA Study of CAR-T Cells in Subjects With Systemic Lupus Erythematosus
- Where
- Wuhan
- Életkor
- 18 év to 65 év
- People
- 24
- Run by
- Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
See details and how to joinNCT06900764 - 1. fázisTaking peopleVunakizumab for the Treatment of Mild to Moderate Systemic Lupus Erythematosus
- Where
- Beijing
- Életkor
- 18 év to 65 év
- People
- 20
- Run by
- Chinese SLE Treatment And Research Group
See details and how to joinNCT06881290 - No phaseTaking peopleCAR-T Cells Therapy for Patients With Autoimmune Diseases
- Where
- Hefei
- Életkor
- 18 év and over
- People
- 18
- Run by
- Anhui Provincial Hospital
See details and how to joinNCT07052565 - 1/2. fázisTaking peopleTreatment of Systemic Lupus Erythematosus With Human Umbilical Cord Mesenchymal Stem Cells
- Where
- Shenzhen
- Életkor
- 18 év to 65 év
- People
- 58
- Run by
- Shenzhen Beike Bio-Technology Co., Ltd.
See details and how to joinNCT07041801 - 1/2. fázisNot yet taking people in KínaMSC303 Subcutaneous Injection for the Treatment of Immunologic Glomerular Disease.
- Where
- Shanghai
- Életkor
- 18 év to 65 év
- People
- 12
- Run by
- Shanghai Changzheng Hospital
See details and how to joinNCT07000292 - No phaseTaking peopleLong-Term Outcomes in SLE at Peking University People's Hospital
- Where
- Beijing
- Életkor
- 18 év and over
- People
- 1000
- Run by
- Peking University People's Hospital
See details and how to joinNCT07005479